Home - Products - Apoptosis - IL Receptor - Aristololactam I

Aristololactam I

CAS No. 13395-02-3

Aristololactam I( —— )

Catalog No. M17961 CAS No. 13395-02-3

Aristololactam I has cytotoxic potency, mediated through the induction of apoptosis in a caspase 3-dependent pathway.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
1 mL x 10 mM in DMSO	176	In Stock
5MG	136	In Stock
10MG	217	In Stock
25MG	370	In Stock
50MG	533	In Stock
100MG	759	In Stock
200MG	Get Quote	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Aristololactam I
Note

Research use only, not for human use.
Brief Description

Aristololactam I has cytotoxic potency, mediated through the induction of apoptosis in a caspase 3-dependent pathway.
Description

Aristololactam I has cytotoxic potency, mediated through the induction of apoptosis in a caspase 3-dependent pathway. The effects of Aristololactam I may be mediated by different mechanisms except TGF-beta1 pathway. 3. Aristololactam I may be one of toxic metabolites in Chinese herbs containing AA which participate in renal damage and fibrosis.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Apoptosis
Target

IL Receptor
Recptor

Caspase-3
Research Area

——
Indication

——

Chemical Information

CAS Number

13395-02-3
Formula Weight

293.27
Molecular Formula

C17H11NO4
Purity

>98% (HPLC)
Solubility

In Vitro:?DMSO : 12.5 mg/mL (42.62 mM)
SMILES

COC1=CC=CC2=C3C4=C(C=C21)NC(=O)C4=CC5=C3OCO5
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

Ordesekimab

Ordesekimab (AMG 714) is a human IgG1 κ-anti-IL-15 (Interleukin Related) monoclonal antibody.
CP 424174

CP 424174 is an inhibitor of IL-1β post-translational processing with IC50 of 210 nM. Inhibits the formation of mature IL-1β. Indirectly inhibits NLRP3. Active in vivo and orally bioavailable.
Siltuximab

Siltuximab（CNTO-328） is a monoclonal antibody with anti-tumor activity targeting IL-6 for the study of giant lymph node hyperplasia (MCD) and COVID-19.

Sign In Join Free